Population pharmacokinetics and exposure-response of filgotinib in patients with moderate to severe Crohn's disease

被引：0
|
作者：
Sharma, Shringi [1 ]
Xin, Yan [1 ]
Gao, Yuying [2 ]
Namour, Florence [3 ]
Mathias, Anita [1 ]
机构：
[1] Gilead Sci, Foster City, CA USA
[2] Certara Strateg Consulting, Menlo Pk, CA USA
[3] Galapagos NV, Mechelen, Belgium
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2016年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
M-54
引用
收藏
页码：S36 / S36
页数：1
相关论文
共 50 条
  • [1] Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease
    Adedokun, Omoniyi J.
    Xu, Zhenhua
    Gasink, Christopher
    Kowalski, Ken
    Sandborn, William J.
    Feagan, Brian
    CLINICAL THERAPEUTICS, 2022, 44 (10) : 1336 - 1355
  • [2] Population Pharmacokinetics and Exposure-Response Relationships of Astegolimab in Patients With Severe Asthma
    Kotani, Naoki
    Dolton, Michael
    Svensson, Robin J.
    Ribbing, Jakob
    Friberg, Lena E.
    Vadhavkar, Shweta
    Cheung, Dorothy
    Staton, Tracy
    Sperinde, Gizette
    Jin, Jin
    Putnam, Wendy S.
    Quartino, Angelica
    JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (07): : 905 - 917
  • [3] Mirikizumab pharmacokinetics and exposure-response in pediatric patients with moderate-to-severe ulcerative colitis
    Otani, Yuki
    Chua, Laiyi
    Komocsar, Wendy J.
    Larkin, Amy
    Johns, Jordan
    Zhang, Xin
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2025, 14 (03): : 474 - 485
  • [4] Pharmacokinetics of Laquinimod in Patients With Active Moderate to Severe Crohn's Disease
    D'Haens, Geert R.
    Sandborn, William
    Colombel, Jean-Frederic
    Mimrod, Dorit
    Spiegelstein, Ofer
    Brown, Kurt
    Feagan, Brian G.
    GASTROENTEROLOGY, 2014, 146 (05) : S368 - S368
  • [5] Pharmacokinetics of laquinimod in patients with active moderate to severe Crohn's disease
    D'Haens, G.
    Sandborn, W. J.
    Rutgeerts, P.
    Colombel, J. F.
    Mimrod, D.
    Spiegelstein, O.
    Brown, K.
    Feagan, B.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S226 - S226
  • [6] Pharmacokinetics of Adalimumab in Pediatric Patients With Moderate to Severe Crohn's Disease
    Eckert, Doerthe
    Mensing, Sven
    Sharma, Shringi
    Thakkar, Roopal
    Robinson, Anne
    Hyams, Jeffrey S.
    Rosh, Joel R.
    Ruemmele, Frank
    Awni, Walid M.
    GASTROENTEROLOGY, 2013, 144 (05) : S228 - S228
  • [7] Population PK/PD Modeling for Evaluation of Filgotinib Efficacy in Subjects with Moderate to Severe Crohn's Disease
    Meng, Amy
    Sharma, Shringi
    Xin, Yan
    Namour, Florence
    Mathias, Anita
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S17 - S17
  • [8] Pharmacokinetics and Exposure-Response Analyses to Support Dose Selection of Upadacitinib in Crohn's Disease
    Bhatnagar, Sumit
    Schlachter, Louisa
    Eckert, Doerthe
    Stodtmann, Sven
    Liu, Wei
    Lacerda, Ana P.
    Mohamed, Mohamed-Eslam F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (05) : 1240 - 1251
  • [9] MIRIKIZUMAB PHARMACOKINETICS AND EXPOSURE-RESPONSE IN A PHASE 2 STUDY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
    Chua, Laiyi
    Otani, Yuki
    Friedrich, Stuart
    Durand, Frederick
    Zhang, Xin
    GASTROENTEROLOGY, 2024, 166 (05) : S822 - S822
  • [10] Mirikizumab Pharmacokinetics and Exposure-Response in a Phase 2 Study in Patients With Moderately to Severely Active Crohn's Disease
    Chua, L.
    Otani, Y.
    Friedrich, S.
    Durand, F.
    Zhang, X.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1873 - I1873
12345